INKmune Publications

search

INKmune Publications

2023 Publications

A Killer Disarmed: Natural Killer Cell Impairment in Myelodysplastic Syndrome.

2022 Publications

In Vivo Generation of Memory-like NK Cells for the Treatment of AML and Myelodysplastic Syndrome; Early Clinical Applications of INKmuneTM

2020 Publications

Killers at the crossroads: The use of innate immune cells in adoptive cellular therapy of cancer

2019 Publications

Tumor- and cytokine-primed human natural killer cells exhibit distinct phenotypic and transcriptional signatures.

Natural killer cell cytotoxicity is a predictor of outcome for patients with high risk myelodysplastic syndrome and oligoblastic acute myeloid leukemia treated with azacytidine.

Characterization of human natural killer cells for therapeutic use.

2018 Publications

Primed to Kill: CTV-1 Stimulated Haploidentical Natural Killer Cells for Consolidation of AML.

A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia.

2017 Publications

Natural killer cells differentiated in vitro from cord blood CD34+ cells are more advantageous for use as an immunotherapy than peripheral blood and cord blood natural killer cells.

2016 Publications

Advances in clinical NK cell studies: Donor selection, manufacturing and quality control.

2015 Publications

Two-Stage Priming of Allogeneic Natural Killer Cells for the Treatment of Patients with Acute Myeloid Leukemia: A Phase I Trial.

2013 Publications

Tumor-primed NK cells: waiting for the green light.

2011 Publications

Tumor-primed natural killer cells from patients with multiple myeloma lyse autologous, NK-resistant, bone marrow-derived malignant plasma cells.

Leukemic priming of resting NK cells is killer Ig-like receptor independent but requires CD15-mediated CD2 ligation and natural cytotoxicity receptors.

2007 Publications

Tumor-primed human natural killer cells lyse NK-resistant tumor targets: evidence of a two-stage process in resting NK cell activation.

This website uses cookies to facilitate the use of the website, improve its performance and security, and personalize the proposed content.